These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 4405359)

  • 1. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia.
    Bortin MM; Rimm AA; Saltzstein EC
    Science; 1973 Feb; 179(4075):811-3. PubMed ID: 4405359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 3. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide.
    Truitt RL; Rose WC; Rimm AA; Bortin MM
    Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Albala MM
    Cancer Res; 1975 Mar; 35(3):637-9. PubMed ID: 234789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of normal allogeneic responder cells in mouse mixed leukocyte culture by long-passage AKR leukemic lymphoblasts.
    Rodey GE; Sprader JC; Bortin MM
    Cancer Res; 1974 Jun; 34(6):1289-94. PubMed ID: 4275007
    [No Abstract]   [Full Text] [Related]  

  • 6. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloimmunization and adoptive immunotherapy of leukemia.
    Truitt RL; Shih CY; Rimm AA; Tempelis LD; Bortin MM
    Transplant Proc; 1981 Dec; 13(4):1910-4. PubMed ID: 6949385
    [No Abstract]   [Full Text] [Related]  

  • 8. Graft versus leukemia. 3. Apparent independent anthost and antileukemia activity of transplanted immunocompetent cells.
    Bortin MM; Rimm AA; Saltzstein EC; Rodey GE
    Transplantation; 1973 Sep; 16(3):182-8. PubMed ID: 4147030
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy.
    Chester SJ; Esparza AR; Albala MM
    Cancer Res; 1975 Mar; 35(3):634-6. PubMed ID: 234788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
    Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunochemotherapy of a transplantable AKR leukemia (K36).
    Putman DL; Kind PD; Goldin A; Kende M
    Int J Cancer; 1978 Feb; 21(2):230-3. PubMed ID: 24004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow chimerism in germfree mice. 3. Therapy of leukemic AKR mice.
    Truitt RL; Pollard M; Srivastava KK
    Proc Soc Exp Biol Med; 1974 May; 146(1):153-8. PubMed ID: 4597165
    [No Abstract]   [Full Text] [Related]  

  • 15. Graft versus leukemia. VI. Adoptive immunotherapy in combination with chemoradiotherapy for spontaneous leukemia-lymphoma in AKR mice.
    Bortin MM; Rose WC; Truitt RL; Rimm AA; Saltzstein EC; Rodey GE
    J Natl Cancer Inst; 1975 Nov; 55(5):1227-9. PubMed ID: 1546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft versus leukemia for "cell cure" of long-passage AKR leukemia after chemoradiotherapy.
    Saltzstein EC; Glasspiegel JS; Rimm AA; Giller RH; Bortin MM
    Cancer Res; 1972 Aug; 32(8):1658-62. PubMed ID: 4402951
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification and characterization of a soluble suppressor factor(s) in the serum of AKR mice bearing lymphocytic leukemia.
    Simon JD; Freed BM; Davignon D; Albala MM
    Cell Immunol; 1983 Nov; 82(1):163-73. PubMed ID: 6605807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular immune capacity of mice with transplanted lymphoid leukaemia.
    Boranic M; Poljak-Blazi M
    Biomedicine; 1976 Jun; 25(4):141-4. PubMed ID: 782579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia induction in C3H mice following their inoculation with normal AKR lymphoid cells.
    Nemirovsky T; Trainin N
    Int J Cancer; 1973 Jan; 11(1):172-7. PubMed ID: 4151449
    [No Abstract]   [Full Text] [Related]  

  • 20. Restriction by H-2 gene complex of transfer of cell-mediated immunity to Listeria monocytogenes.
    Zinkernagel RM
    Nature; 1974 Sep; 251(5472):230-3. PubMed ID: 4214309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.